ישראל - עברית - Ministry of Health

סימנס ישראל בע"מ - צוות טכני - שיקוף לצנתורים (קרדיולוגיה התערבותית)

ישראל - עברית - Ministry of Health

a.bee-zee cons.& marketing ltd - lasalocid sodium 15 % - powder - medical additive for the prevention of coccidiosis in broilers and turkeys, cattle and sheep caused by various strains of eimeria.

ישראל - עברית - Ministry of Health

a.bee-zee cons.& marketing ltd - salinomycin sodium 12 %w/w - powder - feed additive for the prevention and treatment of coccidiosis in broilers.

ישראל - עברית - Ministry of Health

a.bee-zee cons.& marketing ltd - decoquinate 6 %w/w - powder - feed additive for the prevention and treatment of coccidiosis in broilers, calves, goats, lambs. for prevention of abortions and perinatal loses due to toxoplasmosis in ewes.

ישראל - עברית - Ministry of Health

a.bee-zee cons.& marketing ltd - maduramicin ammonium 1 %w/w - powder - feed additive for the prevention of coccidiosis in broilers and turkeys, caused by various strains of eimeria.

ישראל - עברית - Ministry of Health

a.bee-zee cons.& marketing ltd - robenidine hydrochloride 6.6 %w/w - premix - feed additive for the prevention and treatment of coccidiosis in broilers, turkeys and rabbits.

ישראל - עברית - Ministry of Health

a.bee-zee cons.& marketing ltd - bacitracin methylene disalicylate 10 %w/w - granules - prevention and treatment of necrotic enteritis in broilers caused by micro-organisms susceptible to bacitracin methylene disalicylate. secondary infection caused by micro-organisms susceptible to bacitracin methylene disalicylate in transmissible enteritis in turkeys.

ישראל - עברית - Ministry of Health

a.bee-zee cons.& marketing ltd - lasalocid sodium - אבקה - lasalocid sodium 15 %

ישראל - עברית - Ministry of Health

teva medical ltd. - migada - אחות - see attached document : us fda 510(k) k051669 approved indications for use

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - niacin 500 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n